Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
ht decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 ht » 5 h (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
ht decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 ht » 5 h (Expand Search)
-
1661
Procedure related data, LBNP, LBPP and hypoxia.
Published 2023“…Decreasing levels of LBNP were applied in 5-minute steps until subjects reached presyncope. …”
-
1662
Individual biometric data of patients.
Published 2023“…Decreasing levels of LBNP were applied in 5-minute steps until subjects reached presyncope. …”
-
1663
-
1664
-
1665
Vectorized siRNA TMPRSS2-ERG IV-SQ impaired tumour growth and restored differentiation <i>in vivo</i>.
Published 2015“…<p><b>a.</b> SCID mice (n = 5/group) bearing VCaP tumour xenografts were injected intravenously either with NaCl 0.9%, non-vectorized siRNA TMPRSS2-ERG IV, NPs siRNA control-SQ or NPs siRNA TMPRSS2-ERG IV-SQ twice per week during 6 weeks (1.8 mg/kg/mouse cumulative dose). …”
-
1666
Different response of visASCs to a micro-local oxygen concentration decrease in metabolically active sites of the adipose tissue.
Published 2017“…However, hypox-visASCs from MS patients show a lower ability to actively participate in or stimulate the formation of microvascular structures, while they favor the accumulation of CD11C<sup>+</sup> and CD163<sup>+</sup> macrophages in the adipose tissue through their contribution to the increased tissue levels of MCP1. ↑ Increased response; <b>↓</b> Decreased response; → Hypox-visASCs main response NonMS: obese subjects without metabolic syndrome; MS: obese subjects with metabolic syndrome; visASC: visceral adipose tissue-derived multipotent mesenchymal cells; hypox-visASCs: visASC under hypoxia; NOX5: NADPH Oxidase 5; SDF1α: stromal cell-derived factor 1α; VEGF: vascular endothelial growth factor; MCP1: monocyte chemoattractant protein 1; CD11C<sup>+</sup>, CD163<sup>+</sup>: proinflammatory macrophage cell-surface markers.…”
-
1667
-
1668
-
1669
-
1670
-
1671
-
1672
-
1673
-
1674
-
1675
-
1676
-
1677
-
1678
A combined algorithm to distinguish between IB and NC models based on the differences in binding kinetics and DynR temporal evolution.
Published 2020“…Predicted <b>DynR</b>(t → 0) according to the value of <i>k</i><sub>10</sub>/<i>k</i><sub>01</sub> obtained from Step 2, indicated with a brown horizontal dashed line. …”
-
1679
-
1680
Low concentrations of siRNA TMPRSS2-ERG III and IV impair TMPRSS2-ERG oncogene and oncoprotein levels but not cell viability.
Published 2015“…<p>VCaP cells were transfected for 72h from 2.5 nM to 50 nM with siRNA TMPRSS2-ERG III, siRNA TMPRSS2-ERG IV or siRNA Control. …”